Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation

TON - March 2018, Vol 11, No 1 - Breast Cancer, Drug Updates & News, ESMO
 Taselisib, a PI3K Inhibitor, Shrinks Tumors in Early Breast Cancer, with Added Activity in Patients with PI3KCA Mutation

For the first time, a randomized clinical trial has shown significant tumor shrinkage with a phosphoinositide-3-kinase (PI3K) inhibitor in patients with estrogen receptor (ER)- positive, HER2-negative early breast cancer. The phase 3 study LORELEI compared neoadjuvant therapy with letrozole plus placebo versus letrozole plus taselisib, a PI3K inhibitor, in this patient population.

“We were able to detect a reduction in tumor size after only 16 weeks of treatment compared with patients who received letrozole plus placebo,” said lead investigator Cristina Saura, MD, PhD, Head, Breast Cancer Unit, Vall d’Hebron University Hospital, Barcelona, Spain, who presented the results at the 2017 European Society for Medical Oncology (ESMO) Congress.

“Any tumor shrinkage is positive for patients, because this means that the drug had activity against their tumor in a short period of time,” she added.

The phase 3 LORELEI study enrolled 334 postmenopausal women with ER-positive, HER2-negative early breast cancer (stages I-III) that was tested for the PI3KCA mutation. Patients receiving letrozole were randomized to taselisib 4 mg (5 days on, 2 days off) or to placebo for 16 weeks, followed by surgery.

More than 60% of patients had stage T2 breast cancer, approximately 60% had grade 2 tumors, and more than 50% had invasive ductal carcinomas. The co-primary end points were objective response rate (ORR) and pathologic complete response.

The study met its primary end point of ORR, which was improved in patients who received taselisib plus letrozole versus the placebo plus letrozole group (50% vs 39.3%, respectively; P = .049). The complete response rate was 4.8% in the taselisib group versus 1.8% in the letrozole group, and the partial response rate was 45.2% versus 35.5%, respectively.

Taselisib achieved more robust ORR in 152 patients with the PI3KCA mutation compared with placebo (56.2% vs 38%; P = .033).

“For me, the main message is that even though all the patients seemed to derive some benefit from taselisib, those with this mutation [PI3KCA] seemed to derive more benefit,” said Dr Saura.

There was no significant difference between the treatment arms, including patients with PI3KCA mutation, in the pathologic complete response.

Taselisib was discontinued in 10.8% of patients and dose reductions were needed in 11.4% of patients. The most common grade 3 or 4 adverse events with taselisib were gastrointestinal disorders (7.8%); infections (4.8%); skin disorders (4.8%); vascular effects (3.6%); and metabolic and nutrition disorders (3.6%).

Taselisib Degrades the PI3KCA Mutation

Taselisib is an oral, potent, selective PI3K inhibitor with enhanced activity against cancer cells with the PI3KCA mutation. The PI3K signaling pathway is involved in cell proliferation and is the most deregulated pathway in HR-positive breast cancer, with approximately 40% of patients showing activating mutations in this pathway, explained Dr Saura. Unlike other PI3K inhibitors under investigation, taselisib degrades PI3KCA mutation—the catalytic subunit of PI3K—by a unique mechanism that distinguishes it from other PI3K inhibitors.

Commenting on the LORELEI study, ESMO expert Sibylle Loibl, MD, PhD, said, “The alpha-specific story is important, because other PI3K inhibitors have had only a small effect, and the benefit–risk ratio was less favorable. In general, it is believed that the alpha-specific inhibitors will be more efficacious and less toxic than other PI3K inhibitors.”

“These are the first data indicating that the addition of an alpha-­specific PI3K inhibitor may work in addition to endocrine therapy in HER2-negative, HR-positive breast cancer. More data from LORELEI, as well as data from the phase 3 studies in metastatic breast cancer are needed to evaluate the role of PI3K inhibitors in breast cancer,” concluded Dr Loibl.</p

Related Items
Acquired HER2 Mutations in Metastatic Breast Cancer Confer Resistance to ER-Directed Therapy
Phoebe Starr
TON - July 2018, Vol 11, No 3 published on July 25, 2018 in Breast Cancer
Explaining Treatment Regimens to Patients with HR+/HER2- Metastatic Breast Cancer
Thomas Bachelot, MD, PhD
Video Library published on July 19, 2018 in Breast Cancer, Video
HR+/HER2- Metastatic Breast Cancer: Common Presenting Symptoms
Hope S. Rugo, MD
Video Library published on July 19, 2018 in Breast Cancer, Video
Kisqali (Ribociclib): Second CDK4/CDK6 Inhibitor Approved for Postmenopausal Women with HR-Positive, HER2-Negative Advanced Breast Cancer
Lisa A. Raedler, PhD, RPh, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Verzenio (Abemaciclib) a New CDK4/CDK6 Inhibitor Approved for HR-Positive, HER2-Negative Advanced or Metastatic Breast Cancer
Loretta Fala, Medical Writer
2018 Third Annual Oncology Guide to New FDA Approvals published on May 9, 2018 in FDA Approvals, News & Updates, Breast Cancer
Immunotherapy Combination Shows Promising Results in HER2 1+/2+ Breast Cancer
TOP - May 2018, Vol 11, No 1 published on May 1, 2018 in Adverse Effects, Breast Cancer
Breaking News: Sellas Announces Promising Data on NeuVax in Combination with Herceptin in HER2 1+/2+ Breast Cancer
TOP Web Exclusives published on April 7, 2018 in Breast Cancer, Online Only
Ivosidenib, New IDH1 Inhibitor, Elicits Complete Response in Relapsed Acute Myeloid Leukemia
Wayne Kuznar
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Conference Correspondent, Drug Updates & News, ASH
The Challenges of Oral Cancer Drugs Use and Side-Effects Management
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in ESMO, Drug Updates & News, Side-Effects Management
Silent Patients Find Their Voices Through an Advocate’s Journey
Meg Barbor, MPH
TON - March 2018, Vol 11, No 1 published on March 9, 2018 in Patient Advocacy, Conference Correspondent, ESMO
Last modified: May 23, 2018